Research programme: mRNA therapeutics - Almirall/eTheRNA Immunotherapies
Latest Information Update: 21 Dec 2023
At a glance
- Originator Almirall S.A.; eTheRNA Immunotherapies
- Class Antineoplastics; RNA; Skin disorder therapies
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Skin cancer; Skin disorders